viewGenedrive PLC

Genedrive gains as it reports high clinical accuracy for infant hearing loss test

The kit is designed to screen babies for a genetic mutation, MT-RNR1, which if present, can cause lifelong deafness if they are prescribed with the antibiotic gentamicin

Genedrive PLC - Genedrive’s infant hearing loss test reports high clinical accuracy

Genedrive PLC’s (LON:GDR) shares surged on Tuesday as the company achieved “high clinical accuracy” in a recent trial of its screening test designed to reduce the risk of antibiotic-induced hearing loss in infants.

The diagnostics firm said the test had achieved a diagnostic sensitivity of 100% and a specificity of 100% across 303 samples and was unaffected by common bacteria and interfering substances that may be found in a patient.

WATCH: Genedrive's David Budd hails CE mark for its infant hearing loss test

Genedrive’s kit is designed to be used in critical care settings to screen babies for a genetic mutation, MT-RNR1, which if present, can cause lifelong deafness if they are prescribed with the antibiotic gentamicin.

In a statement, David Budd, the company’s chief executive, said the next step for the test will be an implementation study at hospitals in Manchester and Liverpool, with the goal being “not only to replicate the analytical performance outcomes but also to ensure the test can be implemented in an NHS environment”.

He noted that the firm will also be looking to establish commercial opportunities for the test across parts of the EU following the award of a European standard CE marking last month.

The group's house broker Peel Hunt retained their 'buy' rating and 42p target price, saying the news was "a positive development for the Genedrive platform".

In early trading, the shares jumped 14% to 24.5p.

--Adds broker comment and share price--


Quick facts: Genedrive PLC

Price: 92 GBX

Market: AIM
Market Cap: £47.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...



Genedrive's David Budd details launch of its unique coronavirus test kits...

Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version...

on 29/5/20

2 min read